Litcius/Paper detail

Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer

Filipa Lynce, James T. Williams, Meredith M. Regan, Craig A. Bunnell, Rachel A. Freedman, Sara M. Tolaney, Wendy Y. Chen, Erica L. Mayer, Ann H. Partridge, Eric P. Winer, Beth Overmoyer

2021Cancer Chemotherapy and Pharmacology34 citationsDOI

Topics & Concepts

MedicineRuxolitinibInternal medicineNeutropeniaOncologyBreast cancerMetastatic breast cancerCancerChemotherapyGastroenterologyBone marrowMyelofibrosisCytokine Signaling Pathways and InteractionsHER2/EGFR in Cancer ResearchCancer Immunotherapy and Biomarkers
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer | Litcius